Survival of untreated DLBCL patients on North Central Cancer Treatment Group Trial N0489 by pretreatment serum IL-10 levels. (A) The median value of serum IL-10 was used to group patients into high and low IL-10 cohorts. The EFS of patients with low serum IL-10 (≤ 26 pg/mL) and high serum IL-10 (> 26 pg/mL) was estimated by the Kaplan-Meier method. (B) Distribution of IL-10 between genetic types of DLBCL as determined by the Hans IHC method. Thirty-nine patients had both serum IL-10 and tissue available for comparison.